Skip to content


  • Case report
  • Open Access

Failure of malaria chemoprophylaxis with mefloquine in an oversize traveller to Mozambique

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
Malaria Journal201312:451

  • Received: 23 July 2013
  • Accepted: 16 December 2013
  • Published:


A case of failure of mefloquine prophylaxis in an oversize traveller, who correctly took the drug. This case seems to be attributed to mefloquine resistance, however it is suggested that mefloquine dosage should be modulated by body weight, as is already indicated by some authorities.


  • Failure
  • Mefloquine
  • Chemoprophylaxis
  • Malaria


The correct dosage for mefloquine in anti-malarial chemoprophylaxis is 5 mg/kg [1]. The vast majority of international [2, 3] and national [4] guidelines on malaria prevention suggests a prophylactic dose of 250 mg per week in adult travellers. However, regardless the product label, some national Travel Medicine Societies, such as the Swiss and the Austrian ones, suggest to modulate the drug dosage by body weight (Table 1) [5, 6]: 1 ½ tablet per week for patients weighing > 90 kg, two tablets per week for the patients weighing > 120 kg. The dosage issue concerns not only the overweight, but also the low weight travellers. Those weighing < 60 kg may poorly tolerate a whole tablet of mefloquine per week [79].
Table 1

Dosage of mefloquine tablet (250 mg) in Swiss/Austrian malaria prophylaxis recommendations

> 120 kg

2 tablets (twice weekly on tablet: e.g. Mon & Thu)

> 90 kg

1 and ½ tablets (twice weekly on tablet: e.g. Mon & Thu)

> 60 kg

1 tablet

40-60 kg

¾ tablet

20-40 kg

½ tablet

10-20 kg

¼ tablet

< 10 kg

5 mg /kg

A case is presented of mefloquine failure in an oversize traveller, that was initially attributed to insufficient dosage.

Case presentation

A 50-year-old Italian patient was admitted to the Centre for Tropical Diseases (CTD) with fever (39°C) and diarrhoea since three days. He reported having visited many Catholic missions over several years (he is a priest) in sub-Saharan Africa, Asia and Latin America. The average length of stay was between 10 and 14 days. He had been vaccinated against yellow fever, hepatitis A and B, and typhoid fever. From 20th to 31st March 2012, he had travelled to Mozambique, regularly taking malaria chemoprophylaxis with mefloquine, one tablet (250 mg) weekly, starting one week before travelling and continuing for four weeks after return: he took the last tablet on 24th April. He presented to CTD on May 18th 2012. His weight was 144 kg. He had no history of alcohol, tobacco or illicit drugs abuse. He was not under any long-term medication. The hearth rate was 90 beats per minute and the blood pressure 140/70 mm Hg. Physical examination was unremarkable, except for a distended abdomen. Quantitative buffy coat (QBC), antigen malarial test and blood smears resulted positive for Plasmodium falciparum malaria, with a parasitaemia of 0.13% (6330 /μl). The blood tests showed 7430 WBC/μl, C reactive protein 142 mg/L. The patient was treated with artemether (tablet 50 mg), eight tablets the first day, then three tablets/day until the fifth day, followed by four tablets of sulphamethoxypyrazine/pyrimethamine 500 mg/25 mg (artemisinin-based combination artemisinin-based combination therapies were not yet available). After two days of treatment, blood films resulted negative and remained so at follow-up, one month later.

Whole blood and plasma mefloquine concentrations were retrospectively evaluated on cryo- preserved (-80°C) samples taken on admission (25 days after the last mefloquine intake), by high pressure liquid chromatography (HPLC) coupled with ultraviolet diode-array detection [10, 11].

Whole blood and plasma mefloquine concentrations were 516 and 320 ng/mL, respectively.


Despite a correct anti-malarial chemoprophylaxis, the patient developed P. falciparum malaria. Therefore, it was concluded that either the strain of P. falciparum was resistant to mefloquine, or its dose was insufficient according to the patient’s body weight. At first, the failure was attributed to an insufficient dosage according to the patient’s weight (144 kg), but later mefloquine concentration was assessed on pre-treatment plasma and blood samples that had been stored.

The mefloquine level in the patient’s bloodstream at admission was within the expected range, considering the breakthrough mefloquine levels >620 ng/ml and a half-life of 21 days (Product information Lariam®, Roche, the Netherlands). Considering these data, P. falciparum resistance to mefloquine was more probable, despite the limitation of a single point in time determination.

A review of literature was performed to collect the characteristics and probable causes of reported cases of failure of mefloquine prophylaxis. PubMed was searched using the following keywords: mefloquine, chemoprophylaxis, failure, Africa. Thirteen papers were retrieved [1224], describing a total of 31 cases (Table 2). Only three cases were reported in the last 15 years, while the others were reported between 1990 and 1998. In most of the cases (25/31) the infection had been acquired in West Africa, in six cases in East Africa (one each in Malawi, Tanzania, Madagascar, Mozambique, and two in Somalia). Six patients were females and 25 males; six were children and 25 were adults between 18 and 50 years of age. Three patients developed P. falciparum malaria while in the endemic country, 28 patients after return. In the latter group, 16 travellers became ill within four weeks after return (still under prophylaxis) and 12 developed the disease after the last dose of mefloquine. The median onset of symptoms after return was 28 days (range 3–91 days). In all cases resistance to mefloquine was presumed, although for some of them drug concentration in plasma was not available.
Table 2

Papers describing mefloquine prophylaxis failure in travellers to Africa




Country of infection

Symptoms onset (before return)

Symptoms onset (days after return)

Callen (2006)






Wichmann (2003)






Gary-Toussaint (2002)






Gizolme (1998)

40, 12, 9

F, M, F



63, 77, 91

Lobel (1998)

31, 22, 30, 26, 25

M, M, M, F, M

Niger, Sierra Leone, Cameroon, RCA



Matteelli (1995)






Magill (1993)











Raccurt (1991)

3, 30, 28, 22, 40, 44, 23, 23, 27

F, M, M, M, M, M, M, M, M

Senegal, Burkina Faso, Niger, Nigeria, Mali, Ivory Coast, Togo


3, 4, 6, 13, 15, 19, 21, 25, 26

Ringwald (1990)

5, 28, 34, 37

M, M, M, M,

Burkina Faso, RCA, Madagascar, Togo


19, 26, 31, 32

Ooi (1991)



Malawi, Kenya



Durieux (1990)



Burkina Faso



Gay (1990)



Senegal, Ivory coast



Bricaire (1990)

6, 34, 40, 45, 50

M, M, M, M, F

Mali, Sierra Leone, Senegal, RCA


7, 30, 45, 46, 61

In relation to the first suspicion, there is no agreement on the need to adjust mefloquine regimen to body weight. It is worth considering this factor, though, also taking into account the lipophilic behaviour of this drug, which has an apparent volume of distribution between 13 to 40 1 kg-1 with a mean of 20 1 kg-1. Both apparent volume of distribution and individual systemic clearance are probably influenced by body fat, thus causing different pharmacokinetic profiles [7, 25, 26].

In conclusion, although in this case the failure of mefloquine prophylaxis was most probably due to drug resistance, the indication given by some scientific societies that mefloquine dosage should be modulated by body weight seems reasonable and should probably be considered in new guidelines.


Written informed consent was obtained from the patient for the publication of this report.


Authors’ Affiliations

Centre for Tropical Diseases, Sacro Cuore-Don Calabria Hospital, Verona, Negrar, Italy
Oncology Department, Sacro Cuore-Don Calabria Hospital, Verona, Negrar, Italy


  1. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG: Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data. MalarJ. 2011, 10: 292-10.1186/1475-2875-10-292.View ArticleGoogle Scholar
  2. CDC: Health Information for International Travel. 2012, The yellow book,,Google Scholar
  3. WHO: International travel and health. 2012, Geneva: World Health Organization,,Google Scholar
  4. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell DA, Bannister BA: UK malaria treatment guidelines. J Infection. 2007, 54: 111-121. 10.1016/j.jinf.2006.12.003.View ArticleGoogle Scholar
  5. DTG: Empfehlungen zur Malaravorbeugung. 2011,,Google Scholar
  6. Hatz C, Nothdurft H: Malaria protection for short-term travelers. Internist. 2006, 47 (8): 810-812. 10.1007/s00108-006-1653-4. 814–817View ArticlePubMedGoogle Scholar
  7. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH: Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol. 2004, 57: 506-512. 10.1046/j.1365-2125.2003.02035.x.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R: Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003, 327: 1078-10.1136/bmj.327.7423.1078.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Ollivier L, Tifratene K, Josse R, Keundjian A, Boutin JP: The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study. Ann Trop Med Parasitol. 2004, 98: 639-641. 10.1179/000349804225021262.View ArticlePubMedGoogle Scholar
  10. Green MD, Bergqvist Y, Mount DL, Corbett S, D'Souza MJ: Improved validated assay for the determination of mefloquine and its carboxy metabolite in plasma, serum and whole blood using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999, 727: 159-165. 10.1016/S0378-4347(99)00080-8.View ArticlePubMedGoogle Scholar
  11. Gutman J, Green M, Durand S, Rojas OV, Ganguly B, Quezada WM, Utz GC, Slutsker L, Ruebush TK, Bacon DJ: Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. Malar J. 2009, 8: 58-10.1186/1475-2875-8-58.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Callen EC, Church CO: Plasmodium falciparum malaria associated with mefloquine failure in Gambia. Pharmacotherapy. 2006, 26: 1526-1528. 10.1592/phco.26.10.1526.View ArticlePubMedGoogle Scholar
  13. Wichmann O, Betschart B, Loscher T, Nothdurft HD, Sonnenburg FV, Jelinek T: Prophylaxis failure due to probable mefloquine resistant P. falciparum from Tanzania. Acta Trop. 2003, 86: 63-65. 10.1016/S0001-706X(03)00003-2.View ArticlePubMedGoogle Scholar
  14. Gari-Toussaint M, Pradines B, Mondain V, Keundjian A, Dellamonica P, Le Fichoux Y: [Senegal and malaria. True prophylactic failure of mefloquine] (in French). Presse Med. 2002, 31: 1136-PubMedGoogle Scholar
  15. Gizolme D, Receveur MC, Bouzidi P, Theron P: [Relative failure of mefloquine chemoprophylaxis on the occasion of a trip to Togo. 3 cases within the same family] (in French). Presse Med. 1998, 27: 1575-1576.PubMedGoogle Scholar
  16. Lobel HO, Varma JK, Miani M, Green M, Todd GD, Grady K, Barber AM: Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers’ health. Am J Trop Med Hyg. 1998, 59: 129-132.PubMedGoogle Scholar
  17. Matteelli A, Chiodera A, Castelli F, Caligaris S, Minardi C, Carosi G: Failure of mefloquine chemoprophylaxis for malaria in Mozambique. J Travel Med. 1995, 2: 260-261. 10.1111/j.1708-8305.1995.tb00673.x.View ArticlePubMedGoogle Scholar
  18. Magill AJ, Smoak BL: Failure of mefloquine chemoprophylaxis for malaria in Somalia. N Engl J Med. 1993, 329: 1206-View ArticlePubMedGoogle Scholar
  19. Raccurt CP, Dumestre-Toulet V, Abraham E, Le Bras M, Brachet-Liermain A, Ripert C: Failure of falciparum malaria prophylaxis by mefloquine in travelers from West Africa. Am J Trop Med Hyg. 1991, 45: 319-324.PubMedGoogle Scholar
  20. Ooi WW: Failure of mefloquine prophylaxis in east Africa. N Engl J Med. 1991, 324 (2): 130-PubMedGoogle Scholar
  21. Durieux I, Boibieux A, Biron F, Ringwald P, Piens MA, Peyramond D: [Failure of chemoprevention with mefloquine in western Africa] (in French). Presse Med. 1990, 19 (33): 1548-1549.PubMedGoogle Scholar
  22. Ringwald P, Bartczak S, Le Bras J, Bricaire F, Matheron S, Bauchet J, Coulaud JP: Failure of anti-malarial prophylaxis with mefloquine in Africa. Trans R Soc Trop Med Hyg. 1990, 84: 348-349. 10.1016/0035-9203(90)90311-2.View ArticlePubMedGoogle Scholar
  23. Gay F, Binet MH, Bustos MD, Rouveix B, Danis M, Roy C, Gentilini M: Mefloquine failure in child contracting falciparum malaria in West Africa. Lancet. 1990, 335: 120-121. 10.1016/0140-6736(90)90597-X.View ArticlePubMedGoogle Scholar
  24. Bricaire F, Gay F, Caumes E, Datry A, Bustos D, Felix H, Paris L, Danis M, Gentilini M: [Failure of prevention of malaria by mefloquine in West Africa] (in French). Ann Med Onterne. 1990, 141 (6): 512-514.Google Scholar
  25. Karbwang J, White NJ: Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990, 19: 264-279. 10.2165/00003088-199019040-00002.View ArticlePubMedGoogle Scholar
  26. Palmer KJ, Holliday SM, Brogden RN: Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993, 45: 430-475.View ArticlePubMedGoogle Scholar


© Gobbi et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.